Center For Mental Health Vratsa EOOD

The trials here

What the 20 trials at this site are about, from their registry records.

Conditions

• Schizophrenia9 trials
• Depression8 trials
• Bipolar disorder4 trials
• Alzheimer disease1 trial

Phase

• Phase 313 trials
• Phase 25 trials
• Phase 11 trial
• Phase 2/31 trial

Status

• Completed8 trials
• Recruiting8 trials
• Not yet recruiting2 trials
• Suspended2 trials

Lead sponsor

• Neurocrine Biosciences3 trials
• Intra-Cellular Therapies Inc.2 trials
• Karuna Therapeutics, Inc., a Bristol Myers Squibb company2 trials
• Xenon Pharmaceuticals Inc.2 trials
• Bristol-Myers Squibb1 trial
• and 10 more

Running trials

• Recruiting

  Randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety of Roluperidone in adults with negative symptoms of schizophrenia

  2026-525925-19-00· Phase 3· Minerva Neurosciences Inc.· Source

• Recruiting

  A Phase 2 Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults with Schizophrenia (STAR-1)

  2025-524058-32-00· Phase 2· Novartis Pharma AG· Source

• Recruiting

  DT-101 in Adults with Major Depressive Disorder

  2025-522784-15-00· Phase 2· Draig Therapeutics Limited· Source

• Recruiting

  NBI-1117568-SCZ3030: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia

  NCT07105098· Phase 3· Neurocrine Biosciences· Source

• Recruiting

  A Study to Assess the Long-term Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-3)

  NCT06929273· Phase 3· Bristol-Myers Squibb· Source

• Recruiting

  A study to assess the efficacy and safety of ITI-1284 in the treatment of Psychosis Associated with Alzheimer's Disease

  2024-513035-25-00· Phase 2· Intra-Cellular Therapies Inc.· Source

• Recruiting

  NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia

  NCT07114874· Phase 3· Neurocrine Biosciences· Source

• Recruiting

  Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive Disorder

  NCT06830044· Phase 3· Vanda Pharmaceuticals· Source

• Not yet recruiting

  A Randomized, Multiple-Dose, Open-Label, Parallel-Group Study to Evaluate the Pharmacokinetic Profiles of LY03010 and the Relative Bioavailability at Steady-State of LY03010 versus XEPLION® in Patients with Schizophrenia

  2023-508981-13-00· Phase 1· Geneora Pharma (Shijiazhuang) Co. Ltd.· Source

• Recruiting

  A research study to compare the antidepressant ability and safety of Samyr® tablets versus placebo tablets as an adjunct to additional antidepressant treatment in patients with major depressive disorder (MDD)

  2024-513019-29-00· Phase 3· Mylan Inc.· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Schizophrenia5 recruiting
• Depression3 recruiting
• Alzheimer disease1 recruiting
• Bipolar disorder1 recruiting

Closed trials

• Completed

  A study to assess the efficacy and safety of lumateperone in patients with Bipolar Mania

  2024-513036-26-00· Phase 3· Intra-Cellular Therapies Inc.· Source

• Completed

  A Randomized, Double-blind, Multicenter, Placebo-controlled Study of Adjunctive Aticaprant Plus an Antidepressant for Relapse Prevention in Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia

  2024-511057-22-00· Phase 3· Janssen Cilag International· Source

• Completed

  A 14-week, multicentre, double-blind, randomised, placebo-controlled phase II study with an 8-week treatment period to assess the efficacy and tolerability of a fixed dose of BH-200 (250 mg BID) in outpatients with Major Depressive Disorder (MDD)

  2024-513104-34-00· Phase 2· HMNC Holding GmbH· Source

• Completed

  Protocol Lay Person Short Title: A Trial of the Safety and Efficacy of Flexible Doses of SEP-363856 as Adjunctive Therapy in the Treatment of Adults with Major Depressive Disorder.

  2022-500538-27-00· Phase 2/3· Otsuka Pharmaceutical Development And Commercialization Inc.· Source

• Completed

  A 52-week, Open-label Trial of CVL-231 in Adult Participants With Schizophrenia

  NCT05443724· Phase 2· Cerevel Therapeutics LLC· Source

• Completed

  An Extension Study to Assess Long-Term Safety and Tolerability of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia

  NCT05304767· Phase 3· Karuna Therapeutics, Inc., a Bristol Myers Squibb company· Source

• Completed

  Journey Study: Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as Adjunctive Treatment for Schizophrenia

  NCT05110157· Phase 3· Neurocrine Biosciences· Source

• Completed

  A Study to Assess Efficacy and Safety of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia

  NCT05145413· Phase 3· Karuna Therapeutics, Inc., a Bristol Myers Squibb company· Source